Single-domain antibody directed against human glycoprotein VI
Target:
Human glycoprotein VI
Target description:
Glycoprotein VI (GPVI, GP6) is a platelet membrane glycoprotein of the immunoglobulin superfamily and a receptor for collagen. It is involved in collagen-induced platelet adhesion and activation. Ligand binding to GPVI initiates migration to lipid rafts and subsequent dimerization of GPVI, the formation of a signaling complex with the FcR gamma chain, and the recruitment of downstream signaling proteins, including Src family kinases Fyn and Lyn and the adapter protein LAT. This results in thrombus formation via activation of phospholipase C gamma 2. Transduction of signals by GPVI is mediated in an immunoreceptor-based manner and involves its immune-receptor tyrosine-based activation motif (ITAM). GPVI also binds fibrinogen and fibrin, resulting in the support of growth and stabilization of the thrombus.4 Mutations in the gp6 gene cause bleeding disorder platelet-type 11 (BDPLT11), characterized by defective platelet activation and aggregation in response to collagen. Also, platelets may be deficient of GPVI due to inherited or acquired loss of the protein, the latter through i.e. autoantibody-induced receptor shedding.
Source:
Immunization with and phage-display selection on purified recombinant human GPVI.
Recombinant monoclonal single-domain antibody (Lama glama), purified from HEK293-E 253 cells using rmp-Protein A affinity chromatography.
Product details.
Specificity:
Human GPIV. Q115 blocks collagen-induced platelet activation, GPVI-mediated fibrinogen binding and P-selectin expression and blocks collagen-induced platelet aggregation.
Formulation:
Tagless single-domain antibody in PBS.
Mol. Weight:
28.1 kDa
Ext. Coeff. (ε):
49175 M-1cm-1
A280 at 1g/L:
1.8
Storage:
Shipped on blue ice. Store at 4˚C or -20˚C (aliquots). Addition of 0.02% sodium azide is optional.